ESCO ASTER PTE. LTD., Singapore is a contract development and manufacturing organisation (CDMO) focusing on offering vaccine-, bio-, cell- and gene-therapy development manufacturing services using primarily its proprietary Adherent Tide Motion Platform supplemented by single use suspension and fermentation, downstream bioprocessing and custom bioengineering equipment for client specific therapeutic applications.
This is the second Esco Aster collaborative research unit set up globally after the first Centre of Excellence (COE) with Bioprocessing Technology Institute (BTI), Singapore. Esco Aster hopes to continue to develop more collaborations in Asia Pacific in years to come to work on the booming cell and gene therapy.
MAHE is one of India’s leading academic and research institutions. It has been granted Institution of Eminence status by the Ministry of Human Resource Development, Government of India. MAHE’s strength in the areas of medicine, dental, pharmacy, allied health sciences, life sciences, regenerative medicine, engineering and other areas offer unique opportunities for Corporates, especially in the pharma and biopharma sector, to collaborate on various phases of product development.
-Dr. Raviraja N S, MAHE’s Director, Corporate Relations and Professor of Pharmaceutical Biotechnology “We are excited to sign this agreement with MAHE and we look forward for harnessing the skilled manpower and mentor pool available at MAHE to build our pipeline products and services to our clients. We envision showcasing this research unit to our potential clients and collaborators and also utilizing it as a training centre.”
Through this agreement, both parties aim to facilitate research, development, and commercial plans and activities relating to stem cells or extracellular vesicles. Other fields of study with potential advantages to scientific discoveries are also welcome.
This collaboration opens up potential breakthrough discoveries aiming to drive the biotherapeutics industry.
About Author
